ZA201906944B - Methods of manufacturing of niraparib - Google Patents
Methods of manufacturing of niraparibInfo
- Publication number
- ZA201906944B ZA201906944B ZA2019/06944A ZA201906944A ZA201906944B ZA 201906944 B ZA201906944 B ZA 201906944B ZA 2019/06944 A ZA2019/06944 A ZA 2019/06944A ZA 201906944 A ZA201906944 A ZA 201906944A ZA 201906944 B ZA201906944 B ZA 201906944B
- Authority
- ZA
- South Africa
- Prior art keywords
- niraparib
- manufacturing
- methods
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title 1
- 229950011068 niraparib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/42—Separation; Purification; Stabilisation; Use of additives
- C07C303/44—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762489387P | 2017-04-24 | 2017-04-24 | |
| US201762489415P | 2017-04-24 | 2017-04-24 | |
| PCT/US2018/029131 WO2018200517A1 (en) | 2017-04-24 | 2018-04-24 | Methods of manufacturing of niraparib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201906944B true ZA201906944B (en) | 2023-03-29 |
Family
ID=63919973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/06944A ZA201906944B (en) | 2017-04-24 | 2019-10-22 | Methods of manufacturing of niraparib |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11161834B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3615513B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7179014B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102582624B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN118271233A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018258274C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3060715C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2926255T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL270068B (cg-RX-API-DMAC7.html) |
| MA (1) | MA48475A (cg-RX-API-DMAC7.html) |
| MX (1) | MX393879B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909807TA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI783993B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018200517A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201906944B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| TWI761476B (zh) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)組合物 |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3076859A1 (en) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | Combination therapies and uses thereof |
| TWI825191B (zh) | 2018-10-03 | 2023-12-11 | 美商提薩羅有限公司 | 尼拉帕尼（niraparib）游離鹼之結晶形 |
| CN112300074B (zh) * | 2019-08-02 | 2023-12-29 | 北京盈科瑞创新药物研究有限公司 | 一种吲唑甲酰胺类化合物及其制备方法和应用 |
| JP2025508399A (ja) | 2022-02-15 | 2025-03-26 | テサロ， インコーポレイテッド | 脳がんの処置のためのニラパリブの使用 |
| WO2024142096A1 (en) * | 2022-12-29 | 2024-07-04 | Dr. Reddy’S Laboratories Limited | Process for preparation of niraparib tosylate and its intermediates |
| WO2025017711A1 (en) * | 2023-07-20 | 2025-01-23 | Natco Pharma Limited | An improved process for the preparation of niraparib tosylate monohydrate |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| JP4213771B2 (ja) | 1997-04-23 | 2009-01-21 | 株式会社カネカ | 光学活性アミノ化合物の製造方法 |
| DK2270234T3 (da) | 1997-12-08 | 2013-06-03 | California Inst Of Techn | Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser |
| JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| EP1272967A2 (en) | 2000-03-30 | 2003-01-08 | Maxygen, Inc. | In silico cross-over site selection |
| US6759554B2 (en) | 2001-04-24 | 2004-07-06 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| EP1805164B9 (en) | 2004-09-29 | 2011-09-07 | Mitsubishi Tanabe Pharma Corporation | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| AU2007232297B2 (en) | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
| CA2661605A1 (en) | 2006-08-31 | 2008-03-06 | Schering Corporation | Hydantoin derivatives useful as antibacterial agents |
| GEP20115337B (en) | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| EP2132322A4 (en) | 2007-03-02 | 2013-02-20 | Richmond Chemical Corp | METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE |
| AR065804A1 (es) * | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| WO2008132139A2 (en) | 2007-04-27 | 2008-11-06 | Ucb Pharma S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| EP2401366B1 (en) | 2009-02-26 | 2013-12-18 | Codexis, Inc. | Transaminase biocatalysts |
| JP2010269667A (ja) | 2009-05-20 | 2010-12-02 | Alps Electric Co Ltd | 多回転角度検出装置 |
| US8932836B2 (en) | 2010-08-16 | 2015-01-13 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine |
| CA2819400A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| EP2673260B1 (en) | 2011-02-08 | 2016-08-17 | Pfizer Inc | Glucagon receptor modulator |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| EP3406594A1 (en) | 2012-12-07 | 2018-11-28 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| WO2014088983A1 (en) | 2012-12-07 | 2014-06-12 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| CN106496187A (zh) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| CN106432055A (zh) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| CN106432056A (zh) * | 2016-09-17 | 2017-02-22 | 青岛辰达生物科技有限公司 | 一种尼拉帕布中间体(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的制备方法 |
| TWI761476B (zh) | 2017-03-27 | 2022-04-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)組合物 |
| KR20190130625A (ko) | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| AU2018258274C1 (en) | 2017-04-24 | 2021-12-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| AU2018270112A1 (en) | 2017-05-18 | 2019-12-12 | Tesaro, Inc. | Combination therapies for treating cancer |
| SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| CA3076859A1 (en) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | Combination therapies and uses thereof |
| WO2019133697A1 (en) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
| AU2019215450A1 (en) | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
-
2018
- 2018-04-24 AU AU2018258274A patent/AU2018258274C1/en active Active
- 2018-04-24 CN CN202410234039.3A patent/CN118271233A/zh active Pending
- 2018-04-24 CA CA3060715A patent/CA3060715C/en active Active
- 2018-04-24 EP EP18790167.3A patent/EP3615513B1/en active Active
- 2018-04-24 MA MA048475A patent/MA48475A/fr unknown
- 2018-04-24 JP JP2019557567A patent/JP7179014B2/ja active Active
- 2018-04-24 SG SG11201909807T patent/SG11201909807TA/en unknown
- 2018-04-24 TW TW107113922A patent/TWI783993B/zh active
- 2018-04-24 CN CN201880040321.0A patent/CN110753684A/zh active Pending
- 2018-04-24 KR KR1020197034673A patent/KR102582624B1/ko active Active
- 2018-04-24 IL IL270068A patent/IL270068B/en unknown
- 2018-04-24 ES ES18790167T patent/ES2926255T3/es active Active
- 2018-04-24 MX MX2019012658A patent/MX393879B/es unknown
- 2018-04-24 US US16/608,059 patent/US11161834B2/en active Active
- 2018-04-24 WO PCT/US2018/029131 patent/WO2018200517A1/en not_active Ceased
-
2019
- 2019-10-22 ZA ZA2019/06944A patent/ZA201906944B/en unknown
-
2021
- 2021-08-09 AU AU2021215116A patent/AU2021215116B2/en active Active
- 2021-10-29 US US17/452,928 patent/US11629137B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3060715A1 (en) | 2018-11-01 |
| EP3615513B1 (en) | 2022-07-20 |
| US20220041575A1 (en) | 2022-02-10 |
| TW201841889A (zh) | 2018-12-01 |
| AU2018258274A1 (en) | 2019-11-14 |
| IL270068B (en) | 2022-06-01 |
| CN118271233A (zh) | 2024-07-02 |
| ES2926255T3 (es) | 2022-10-24 |
| US20200055837A1 (en) | 2020-02-20 |
| MA48475A (fr) | 2020-03-04 |
| KR102582624B1 (ko) | 2023-09-22 |
| CA3060715C (en) | 2024-10-01 |
| AU2021215116A1 (en) | 2021-08-26 |
| NZ758948A (en) | 2024-04-26 |
| KR20200021456A (ko) | 2020-02-28 |
| WO2018200517A1 (en) | 2018-11-01 |
| SG11201909807TA (en) | 2019-11-28 |
| US11161834B2 (en) | 2021-11-02 |
| EP3615513A1 (en) | 2020-03-04 |
| AU2018258274B2 (en) | 2021-05-13 |
| JP2020517668A (ja) | 2020-06-18 |
| JP7179014B2 (ja) | 2022-11-28 |
| BR112019022320A2 (pt) | 2020-05-26 |
| AU2018258274C1 (en) | 2021-12-02 |
| CN110753684A (zh) | 2020-02-04 |
| EP3615513A4 (en) | 2020-12-09 |
| US11629137B2 (en) | 2023-04-18 |
| AU2021215116B2 (en) | 2022-12-01 |
| MX393879B (es) | 2025-03-24 |
| TWI783993B (zh) | 2022-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906944B (en) | Methods of manufacturing of niraparib | |
| GB2549653B (en) | Additive manufacturing of metallic structures | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| GB201516516D0 (en) | Process of manufacture | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| GB201806072D0 (en) | Methods of manufacture | |
| GB201716774D0 (en) | Method of manufacturing fluorescent-material-containing member | |
| GB2522719B (en) | Method of manufacture | |
| IL265628A (en) | Solid state forms of valbenazine | |
| GB2571413B (en) | Methods of manufacturing hydrogen | |
| GB201511156D0 (en) | Production of alkaloids | |
| ZA201706282B (en) | Solid forms of menaquinols | |
| GB2553390B (en) | Method of manufacture | |
| GB2548706B (en) | Method of manufacturing fluorescent-material-containing member | |
| GB201609314D0 (en) | Methods of forming compounds | |
| GB201805904D0 (en) | Methods of Manufacture | |
| GB201609170D0 (en) | Method of manufacture | |
| GB201718144D0 (en) | Manufacturing method | |
| GB2522716B (en) | Method of manufacture | |
| GB201613971D0 (en) | Method of manufacture | |
| GB201609171D0 (en) | Method of manufacture | |
| GB201601249D0 (en) | Production of manool | |
| IL263300A (en) | METHODS FOR THE PRODUCTION OF CERTAIN CONVERSIONED SULPLAYIMINS | |
| GB201704816D0 (en) | Method of manufacture | |
| IL254666A0 (en) | Crystalline forms of Aldecalcitol |